Silencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice

Science Translational Medicine

Volumn 6, Issue 217, 2014, Pages

  Brock, Amy ^a,e   Krause, Silva ^b   Li, Hu ^a,f   Kowalski, Marek ^a   Goldberg, Michael S ^c   Collins, James J ^a,d   Ingber, Donald E ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BOSTON UNIVERSITY   (United States)

^e The University of Texas at Austin   (United States)

^f MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROGESTERONE RECEPTOR; SMALL INTERFERING RNA;

ACINAR CELL; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST EPITHELIUM; CANCER INCIDENCE; CANCER PREVENTION; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE SILENCING; HOXA1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTRADUCTAL CARCINOMA; INTRADUCTAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ONCOGENE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TUMOR GROWTH; TUMOR SPHEROID;

ANIMALS; DISEASE PROGRESSION; GENE REGULATORY NETWORKS; GENE SILENCING; HOMEODOMAIN PROTEINS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NANOPARTICLES; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 84892507801     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007048     Document Type: Article

References (48)

1. J. F. Simpson, Update on atypical epithelial hyperplasia and ductal carcinoma in situ. Pathology 41, 36-39 (2009).
2. C. J. Allegra, D. R. Aberle, P. Ganschow, S.M. Hahn, C. N. Lee, S.Millon-Underwood, M. C. Pike, S. D. Reed, A. F. Saftlas, S. A. Scarvalone, A. M. Schwartz, C. Slomski, G. Yothers, R. Zon, National Institutes of Health State-of-the-Science Conference statement: Diagnosis and management of ductal carcinoma in situ September 22-24, 2009. J. Natl. Cancer Inst. 102, 161-169 (2010).
3. R. K. Jain, R.Mehta, R.Dimitrov, L. G. Larsson, P. M. Musto, K. B. Hodges, T. M. Ulbright, E.M. Hattab, N. Agaram, M. T. Idrees, S. Badve, Atypical ductal hyperplasia: Interobserver and intraobserver variability. Mod. Pathol. 24, 917-923 (2011).
4. W. L. Betsill Jr., P. P. Rosen, P. H. Lieberman, G. F. Robbins, Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA 239, 1863-1867 (1978).
5. V. Eusebi, E. Feudale, M. P. Foschini, A. Micheli, A. Conti, C. Riva, S. Di Palma, F. Rilke, Longterm follow-up of in situ carcinoma of the breast. Semin. Diagn. Pathol. 11, 223-235 (1994).
6. M. E. Sanders, P. A. Schuyler, W. D. Dupont, D. L. Page, The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103, 2481-2484 (2005).
7. B. Fisher, J. P. Costantino, D. L. Wickerham, C. K. Redmond, M. Kavanah, W. M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-Chiu, L. Ford, N. Wolmark, Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371-1388 (1998).
8. M. Dowsett, A. Goldhirsch, D. F. Hayes, H. J. Senn, W. Wood, G. Viale, International Webbased consultation on priorities for translational breast cancer research. Breast Cancer Res. 9, R81 (2007).
9. I. Tekedereli, S. N. Alpay, U. Akar, E. Yuca, C. Ayugo-Rodriguez, H. D. Han, A. K. Sood, G. Lopez-Berestein, B. Ozpolat, Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (-) and ER (+) breast cancer. Mol. Ther. Nucleic Acids 2, e121 (2013).
10. S. Ohno, M. Takanashi, K. Sudo, S. Ueda, A. Ishikawa, N.Matsuyama, K. Fujita, T.Mizutani, T. Ohgi, T. Ochiya, N. Gotoh, M. Kuroda, Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21, 185-191 (2013).
11. H. M. Aliabadi, R. Maranchuk, C. Kucharski, P. Mahdipoor, J. Hugh, H. Uludaǧ, Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy. J. Control. Release 172, 219-228 (2013).
12. J. C. Burnett, J. J. Rossi, K. Tiemann, Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 6, 1130 -1146 (2011).
13. S. M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, T. Tuschl, Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001).
14. A. Fire, S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, C. C. Mello, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998).
15. K. A. Whitehead, R. Langer, D. G. Anderson, Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129-138 (2009).
16. M. S. Goldberg, D. Xing, Y. Ren, S. Orsulic, S. N. Bhatia, P. A. Sharp, Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc. Natl. Acad. Sci. U.S.A. 108, 745-750 (2011).
17. Y. Huang, J. Hong, S. Zheng, Y. Ding, S. Guo, H. Zhang, X. Zhang, Q. Du, Z. Liang, Elimination pathways of systemically delivered siRNA. Mol. Ther. 19, 381-385 (2011).
18. J. E. Green, M. A. Shibata, K. Yoshidome, M. L. Liu, C. Jorcyk, M. R. Anver, J. Wigginton, R. Wiltrout, E. Shibata, S. Kaczmarczyk, W. Wang, Z. Y. Liu, A. Calvo, C. Couldrey, The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: Ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19, 1020-1027 (2000).
19. M. A. Shibata, C. L. Jorcyk, M. L. Liu, K. Yoshidome, L. G. Gold, J. E. Green, The C3(1)/SV40 T antigen transgenic mouse model of prostate and mammary cancer. Toxicol. Pathol. 26, 177-182 (1998).
20. D. di Bernardo, M. J. Thompson, T. S. Gardner, S. E. Chobot, E. L. Eastwood, A. P. Wojtovich, S. J. Elliott, S. E. Schaus, J. J. Collins, Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks. Nat. Biotechnol. 23, 377-383 (2005).
21. H. Xing, T. S. Gardner, The mode-of-action by network identification (MNI) algorithm: A network biology approach for molecular target identification. Nat. Protoc. 1, 2551-2554 (2006).
22. M. Cantile, G. Pettinato, A. Procino, I. Feliciello, L. Cindolo, C. Cillo, In vivo expression of the whole HOX gene network in human breast cancer. Eur. J. Cancer 39, 257-264 (2003).
23. A. Chariot, V. Castronovo, Detection of HOXA1 expression in human breast cancer. Biochem. Biophys. Res. Commun. 222, 292-297 (1996).
24. X. Zhang, T. Zhu, Y. Chen, H. C. Mertani, K. O. Lee, P. E. Lobie, Human growth hormoneregulated HOXA1 is a human mammary epithelial oncogene. J. Biol. Chem. 278, 7580-7590 (2003).
25. X. J. Ma, Z. Wang, P. D. Ryan, S. J. Isakoff, A. Barmettler, A. Fuller, B. Muir, G. Mohapatra, R. Salunga, J. T. Tuggle, Y. Tran, D. Tran, A. Tassin, P. Amon, W. Wang, W. Wang, E. Enright, K. Stecker, E. Estepa-Sabal, B. Smith, J. Younger, U. Balis, J. Michaelson, A. Bhan, K. Habin, T. M. Baer, J. Brugge, D. A. Haber, M. G. Erlander, D. C. Sgroi, A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607- 616 (2004).
26. C.M. Perou, T. Sørlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lønning, A. L. Børresen-Dale, P. O. Brown, D. Botstein, Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
27. J. R. Pollack, T. Sørlie, C. M. Perou, C. A. Rees, S. S. Jeffrey, P. E. Lonning, R. Tibshirani, D. Botstein, A. L. Børresen-Dale, P. O. Brown, Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc. Natl. Acad. Sci. U.S.A. 99, 12963- 12968 (2002).
28. L. Radvanyi, D. Singh-Sandhu, S. Gallichan, C. Lovitt, A. Pedyczak, G. Mallo, K. Gish, K. Kwok, W. Hanna, J. Zubovits, J. Armes, D. Venter, J. Hakimi, J. Shortreed,M. Donovan, M. Parrington, P. Dunn, R. Oomen, J. Tartaglia, N. L. Berinstein, The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 102, 11005-11010 (2005).
29. S. Ramaswamy, K. N. Ross, E. S. Lander, T. R. Golub, A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33, 49-54 (2003).
30. T. Sørlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P. O. Brown, D. Botstein, P. E. Lønning, A. L. Børresen-Dale, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 98, 10869-10874 (2001).
31. Y. H. Huang, Y. Bao, W. Peng, M. Goldberg, K. Love, D. A. Bumcrot, G. Cole, R. Langer, D. G. Anderson, J. A. Sawicki, Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc. Natl. Acad. Sci. U.S.A. 106, 3426-3430 (2009).
32. K. M. Mohankumar, X. Q. Xu, T. Zhu, N. Kannan, L. D. Miller, E. T. Liu, P. D. Gluckman, S. Sukumar, B. S. Emerald, P. E. Lobie, HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42 MAP kinase pathway in human mammary carcinoma cells. Oncogene 26, 3998-4008 (2007).
33. J. R. Barrow, H. S. Stadler, M. R. Capecchi, Roles of Hoxa1 and Hoxa2 in patterning the early hindbrain of the mouse. Development 127, 933-944 (2000).
34. N. Shah, S. Sukumar, The Hox genes and their roles in oncogenesis. Nat. Rev. Cancer 10, 361-371 (2010).
35. T. Svingen, K. F. Tonissen, Altered HOX gene expression in human skin and breast cancer cells. Cancer Biol. Ther. 2, 518-523 (2003).
36. M. Abe, J. Hamada, O. Takahashi, Y. Takahashi, M. Tada, M. Miyamoto, T. Morikawa, S. Kondo, T. Moriuchi, Disordered expression of HOX genes in human non-small cell lung cancer. Oncol. Rep. 15, 797-802 (2006).
37. J. L. Chen, J. Li, K. J. Kiriluk, A. M. Rosen, G. P. Paner, T. Antic, Y. A. Lussier, D. J. Vander Griend, Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression. Clin. Cancer Res. 18, 4291-4302 (2012).
38. K. L. Rice, J. D. Licht, HOX deregulation in acute myeloid leukemia. J. Clin. Invest. 117, 865-868 (2007).
39. Y. Friedmann, C. A. Daniel, P. Strickland, C. W. Daniel, Hox genes in normal and neoplastic mouse mammary gland. Cancer Res. 54, 5981-5985 (1994).
40. M. T. Lewis, Homeobox genes in mammary gland development and neoplasia. Breast Cancer Res. 2, 158-169 (2000).
41. M. Flanagan, S. Love, E. S. Hwang, Status of intraductal therapy for ductal carcinoma in situ. Curr. Breast Cancer Rep. 2, 75-82 (2010).
42. S. M. Love, W. Zhang, E. J. Gordon, J. Rao, H. Yang, J. Li, B. Zhang, X. Wang, G. Chen, B. Zhang, A feasibility study of the intraductal administration of chemotherapy. Cancer Prev. Res. 6, 51-58 (2013).
43. V. Stearns, T. Mori, L. K. Jacobs, N. F. Khouri, E. Gabrielson, T. Yoshida, S. L. Kominsky, D. L. Huso, S. Jeter, P. Powers, K. Tarpinian, R. J. Brown, J. R. Lange, M. A. Rudek, Z. Zhang, T. N. Tsangaris, S. Sukumar, Preclinical and clinical evaluation of intraductally administered agents in early breast cancer. Sci. Transl. Med. 3, 106ra108 (2011).
44. S. Murata, S. L. Kominsky,M. Vali, Z. Zhang, E.Garrett-Mayer, D. Korz, D. Huso, S.D. Baker, J. Barber, E. Jaffee, R. T. Reilly, S. Sukumar, Ductal access for prevention and therapy of mammary tumors. Cancer Res. 66, 638-645 (2006).
45. Y. S. Chun, T. Yoshida, T. Mori, D. L. Huso, Z. Zhang, V. Stearns, B. Perkins, R. J. Jones, S. Sukumar, Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors. Breast Cancer Res. Treat. 135, 201-208 (2012).
46. R. G. Holzer, C. MacDougall, G. Cortright, K. Atwood, J. E. Green, C. L. Jorcyk, Development and characterization of a progressive series of mammary adenocarcinoma cell lines derived from the C3(1)/SV40 large T-antigen transgenic mouse model. Breast Cancer Res. Treat. 77, 65-76 (2003).
47. A. Akinc, A. Zumbuehl, M. Goldberg, E. S. Leshchiner, V. Busini, N. Hossain, S. A. Bacallado, D. N. Nguyen, J. Fuller, R. Alvarez, A. Borodovsky, T. Borland, R. Constien, A. de Fougerolles, J. R. Dorkin, K. Narayanannair Jayaprakash, M. Jayaraman, M. John, V. Koteliansky, M. Manoharan, L. Nechev, J. Qin, T. Racie, D. Raitcheva, K. G. Rajeev, D. W. Sah, J. Soutschek, I. Toudjarska, H. P. Vornlocher, T. S. Zimmermann, R. Langer, D. G. Anderson, A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561-569 (2008).
48. S. Krause, A. Brock, D. Ingber, Intraductal injection for localized drug delivery to the mouse mammary gland. J. Vis. Exp. 80, e50692 (2013).